Return to search

Avalyn Pharma nets $35.5m Series B

Seattle-based Avalyn Pharma Inc, a biopharmaceutical company focused on treating life threatening pulmonary diseases, has secured $35.5 million in Series B financing.

Seattle-based Avalyn Pharma Inc, a biopharmaceutical company focused on treating life threatening pulmonary diseases, has secured $35.5 million in Series B financing. Norwest Venture Partners led the round with participation from Pivotal bioVenture Partners, F-Prime Capital, Novo Holdings A/S, RiverVest Venture Partners and TPG Biotech.

Source: Press Release